NeuroThera Labs Closes First Tranche of Private Placement, Raising C$2.7M

NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., has successfully closed the first tranche of its non-brokered private placement, raising C$2,700,000. The company sold 22,500,000 units at C$0.12 per unit, each consisting of one common share and one common share purchase warrant. The warrants allow holders to purchase additional common shares at US$0.115 per share (approximately C$0.16) until August 12, 2029, and include an acceleration provision tied to potential Nasdaq listing. The company plans to use the net proceeds for general working capital, including evaluating prospective transactions, settling liabilities, and repaying indebtedness to SciSparc Ltd. All securities issued are subject to a four-month and one-day hold period, and the offering awaits final approval from the TSX Venture Exchange. In connection with the first tranche, the company paid C$222,750 in finder's fees and issued 2,812,500 common shares to an arm's length finder. This financing underscores NeuroThera's commitment to advancing its pipeline of novel therapeutics for central nervous system disorders and other underserved health conditions. For more details, visit the original release on NEWMEDIAWIRE.

The closing of this private placement provides NeuroThera with essential capital to support its ongoing operations and strategic initiatives. The company's focus on CNS disorders positions it to address significant unmet medical needs, and this funding will help advance its collaborative projects and innovative drug combinations. The inclusion of an acceleration provision demonstrates confidence in potential Nasdaq listing, which could enhance liquidity and visibility for the company. With the support of its parent company SciSparc Ltd., NeuroThera is well-positioned to navigate the complex regulatory landscape and bring much-needed therapies to market. The successful completion of the first tranche also signals investor confidence in the company's direction and future prospects, as it continues to build value for shareholders while striving to improve patient outcomes.